Cargando…
Rationale and design of the Children’s Oncology Group (COG) study ALTE1621: a randomized, placebo-controlled trial to determine if low-dose carvedilol can prevent anthracycline-related left ventricular remodeling in childhood cancer survivors at high risk for developing heart failure
BACKGROUND: Anthracyclines are widely used in the treatment of childhood cancer. One of the well-recognized side-effects of anthracycline therapy is dose-dependent cardiomyopathy that may progress to heart failure (HF) years after completion of cancer-directed therapy. This study will evaluate the e...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5050602/ https://www.ncbi.nlm.nih.gov/pubmed/27716152 http://dx.doi.org/10.1186/s12872-016-0364-6 |
_version_ | 1782457913614270464 |
---|---|
author | Armenian, Saro H. Hudson, Melissa M. Chen, Ming Hui Colan, Steven D. Lindenfeld, Lanie Mills, George Siyahian, Aida Gelehrter, Sarah Dang, Ha Hein, Wendy Green, Daniel M. Robison, Leslie L. Wong, F. Lennie Douglas, Pamela S. Bhatia, Smita |
author_facet | Armenian, Saro H. Hudson, Melissa M. Chen, Ming Hui Colan, Steven D. Lindenfeld, Lanie Mills, George Siyahian, Aida Gelehrter, Sarah Dang, Ha Hein, Wendy Green, Daniel M. Robison, Leslie L. Wong, F. Lennie Douglas, Pamela S. Bhatia, Smita |
author_sort | Armenian, Saro H. |
collection | PubMed |
description | BACKGROUND: Anthracyclines are widely used in the treatment of childhood cancer. One of the well-recognized side-effects of anthracycline therapy is dose-dependent cardiomyopathy that may progress to heart failure (HF) years after completion of cancer-directed therapy. This study will evaluate the efficacy of low-dose beta-blocker (carvedilol) for HF risk reduction in childhood cancer survivors at highest risk for HF. The proposed intervention has the potential to significantly reduce chronic cardiac injury via interruption of neurohormonal systems responsible for left ventricular (LV) remodeling, resulting in improved cardiac function and decreased risk of HF. The intervention is informed by previous studies demonstrating efficacy in pediatric and adult non-oncology populations, yet remains unstudied in the pediatric oncology population. METHODS/DESIGN: The primary objective of the trial is to determine impact of the intervention on echocardiographic markers of cardiac remodeling and HF risk, including: LV wall thickness/ dimension ratio (LVWT/D; primary endpoint), as well as LV ejection fraction, volume, and blood biomarkers (natriuretic peptides, galectin-3) associated with HF risk. Secondary objectives are to establish safety and tolerability of the 2-year course of carvedilol using: 1) objective measures: hepatic and cardiovascular toxicity, treatment adherence, and 2) subjective measures: participant self-reported outcomes. Two hundred and fifty survivors of childhood cancer (diagnosed <21 years of age), and previously treated with high-dose (≥300 mg/m(2)) anthracyclines will be enrolled in a randomized, double-blind, placebo controlled trial. After baseline assessments, participants will be randomized in a 1:1 ratio to low-dose carvedilol (maximum dose: 12.5 mg/day) or placebo. Carvedilol or placebo is up-titrated (starting dose: 3.125 mg/day) according to tolerability. DISCUSSION: When completed, this study will provide much-needed information regarding a physiologically plausible pharmacological risk-reduction strategy for childhood cancer survivors at high risk for developing anthracycline-related HF. TRIAL REGISTRATION: ClinicalTrials.gov; NCT02717507 |
format | Online Article Text |
id | pubmed-5050602 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-50506022016-10-05 Rationale and design of the Children’s Oncology Group (COG) study ALTE1621: a randomized, placebo-controlled trial to determine if low-dose carvedilol can prevent anthracycline-related left ventricular remodeling in childhood cancer survivors at high risk for developing heart failure Armenian, Saro H. Hudson, Melissa M. Chen, Ming Hui Colan, Steven D. Lindenfeld, Lanie Mills, George Siyahian, Aida Gelehrter, Sarah Dang, Ha Hein, Wendy Green, Daniel M. Robison, Leslie L. Wong, F. Lennie Douglas, Pamela S. Bhatia, Smita BMC Cardiovasc Disord Study Protocol BACKGROUND: Anthracyclines are widely used in the treatment of childhood cancer. One of the well-recognized side-effects of anthracycline therapy is dose-dependent cardiomyopathy that may progress to heart failure (HF) years after completion of cancer-directed therapy. This study will evaluate the efficacy of low-dose beta-blocker (carvedilol) for HF risk reduction in childhood cancer survivors at highest risk for HF. The proposed intervention has the potential to significantly reduce chronic cardiac injury via interruption of neurohormonal systems responsible for left ventricular (LV) remodeling, resulting in improved cardiac function and decreased risk of HF. The intervention is informed by previous studies demonstrating efficacy in pediatric and adult non-oncology populations, yet remains unstudied in the pediatric oncology population. METHODS/DESIGN: The primary objective of the trial is to determine impact of the intervention on echocardiographic markers of cardiac remodeling and HF risk, including: LV wall thickness/ dimension ratio (LVWT/D; primary endpoint), as well as LV ejection fraction, volume, and blood biomarkers (natriuretic peptides, galectin-3) associated with HF risk. Secondary objectives are to establish safety and tolerability of the 2-year course of carvedilol using: 1) objective measures: hepatic and cardiovascular toxicity, treatment adherence, and 2) subjective measures: participant self-reported outcomes. Two hundred and fifty survivors of childhood cancer (diagnosed <21 years of age), and previously treated with high-dose (≥300 mg/m(2)) anthracyclines will be enrolled in a randomized, double-blind, placebo controlled trial. After baseline assessments, participants will be randomized in a 1:1 ratio to low-dose carvedilol (maximum dose: 12.5 mg/day) or placebo. Carvedilol or placebo is up-titrated (starting dose: 3.125 mg/day) according to tolerability. DISCUSSION: When completed, this study will provide much-needed information regarding a physiologically plausible pharmacological risk-reduction strategy for childhood cancer survivors at high risk for developing anthracycline-related HF. TRIAL REGISTRATION: ClinicalTrials.gov; NCT02717507 BioMed Central 2016-10-04 /pmc/articles/PMC5050602/ /pubmed/27716152 http://dx.doi.org/10.1186/s12872-016-0364-6 Text en © The Author(s). 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Study Protocol Armenian, Saro H. Hudson, Melissa M. Chen, Ming Hui Colan, Steven D. Lindenfeld, Lanie Mills, George Siyahian, Aida Gelehrter, Sarah Dang, Ha Hein, Wendy Green, Daniel M. Robison, Leslie L. Wong, F. Lennie Douglas, Pamela S. Bhatia, Smita Rationale and design of the Children’s Oncology Group (COG) study ALTE1621: a randomized, placebo-controlled trial to determine if low-dose carvedilol can prevent anthracycline-related left ventricular remodeling in childhood cancer survivors at high risk for developing heart failure |
title | Rationale and design of the Children’s Oncology Group (COG) study ALTE1621: a randomized, placebo-controlled trial to determine if low-dose carvedilol can prevent anthracycline-related left ventricular remodeling in childhood cancer survivors at high risk for developing heart failure |
title_full | Rationale and design of the Children’s Oncology Group (COG) study ALTE1621: a randomized, placebo-controlled trial to determine if low-dose carvedilol can prevent anthracycline-related left ventricular remodeling in childhood cancer survivors at high risk for developing heart failure |
title_fullStr | Rationale and design of the Children’s Oncology Group (COG) study ALTE1621: a randomized, placebo-controlled trial to determine if low-dose carvedilol can prevent anthracycline-related left ventricular remodeling in childhood cancer survivors at high risk for developing heart failure |
title_full_unstemmed | Rationale and design of the Children’s Oncology Group (COG) study ALTE1621: a randomized, placebo-controlled trial to determine if low-dose carvedilol can prevent anthracycline-related left ventricular remodeling in childhood cancer survivors at high risk for developing heart failure |
title_short | Rationale and design of the Children’s Oncology Group (COG) study ALTE1621: a randomized, placebo-controlled trial to determine if low-dose carvedilol can prevent anthracycline-related left ventricular remodeling in childhood cancer survivors at high risk for developing heart failure |
title_sort | rationale and design of the children’s oncology group (cog) study alte1621: a randomized, placebo-controlled trial to determine if low-dose carvedilol can prevent anthracycline-related left ventricular remodeling in childhood cancer survivors at high risk for developing heart failure |
topic | Study Protocol |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5050602/ https://www.ncbi.nlm.nih.gov/pubmed/27716152 http://dx.doi.org/10.1186/s12872-016-0364-6 |
work_keys_str_mv | AT armeniansaroh rationaleanddesignofthechildrensoncologygroupcogstudyalte1621arandomizedplacebocontrolledtrialtodetermineiflowdosecarvedilolcanpreventanthracyclinerelatedleftventricularremodelinginchildhoodcancersurvivorsathighriskfordevelopingheartfailure AT hudsonmelissam rationaleanddesignofthechildrensoncologygroupcogstudyalte1621arandomizedplacebocontrolledtrialtodetermineiflowdosecarvedilolcanpreventanthracyclinerelatedleftventricularremodelinginchildhoodcancersurvivorsathighriskfordevelopingheartfailure AT chenminghui rationaleanddesignofthechildrensoncologygroupcogstudyalte1621arandomizedplacebocontrolledtrialtodetermineiflowdosecarvedilolcanpreventanthracyclinerelatedleftventricularremodelinginchildhoodcancersurvivorsathighriskfordevelopingheartfailure AT colanstevend rationaleanddesignofthechildrensoncologygroupcogstudyalte1621arandomizedplacebocontrolledtrialtodetermineiflowdosecarvedilolcanpreventanthracyclinerelatedleftventricularremodelinginchildhoodcancersurvivorsathighriskfordevelopingheartfailure AT lindenfeldlanie rationaleanddesignofthechildrensoncologygroupcogstudyalte1621arandomizedplacebocontrolledtrialtodetermineiflowdosecarvedilolcanpreventanthracyclinerelatedleftventricularremodelinginchildhoodcancersurvivorsathighriskfordevelopingheartfailure AT millsgeorge rationaleanddesignofthechildrensoncologygroupcogstudyalte1621arandomizedplacebocontrolledtrialtodetermineiflowdosecarvedilolcanpreventanthracyclinerelatedleftventricularremodelinginchildhoodcancersurvivorsathighriskfordevelopingheartfailure AT siyahianaida rationaleanddesignofthechildrensoncologygroupcogstudyalte1621arandomizedplacebocontrolledtrialtodetermineiflowdosecarvedilolcanpreventanthracyclinerelatedleftventricularremodelinginchildhoodcancersurvivorsathighriskfordevelopingheartfailure AT gelehrtersarah rationaleanddesignofthechildrensoncologygroupcogstudyalte1621arandomizedplacebocontrolledtrialtodetermineiflowdosecarvedilolcanpreventanthracyclinerelatedleftventricularremodelinginchildhoodcancersurvivorsathighriskfordevelopingheartfailure AT dangha rationaleanddesignofthechildrensoncologygroupcogstudyalte1621arandomizedplacebocontrolledtrialtodetermineiflowdosecarvedilolcanpreventanthracyclinerelatedleftventricularremodelinginchildhoodcancersurvivorsathighriskfordevelopingheartfailure AT heinwendy rationaleanddesignofthechildrensoncologygroupcogstudyalte1621arandomizedplacebocontrolledtrialtodetermineiflowdosecarvedilolcanpreventanthracyclinerelatedleftventricularremodelinginchildhoodcancersurvivorsathighriskfordevelopingheartfailure AT greendanielm rationaleanddesignofthechildrensoncologygroupcogstudyalte1621arandomizedplacebocontrolledtrialtodetermineiflowdosecarvedilolcanpreventanthracyclinerelatedleftventricularremodelinginchildhoodcancersurvivorsathighriskfordevelopingheartfailure AT robisonlesliel rationaleanddesignofthechildrensoncologygroupcogstudyalte1621arandomizedplacebocontrolledtrialtodetermineiflowdosecarvedilolcanpreventanthracyclinerelatedleftventricularremodelinginchildhoodcancersurvivorsathighriskfordevelopingheartfailure AT wongflennie rationaleanddesignofthechildrensoncologygroupcogstudyalte1621arandomizedplacebocontrolledtrialtodetermineiflowdosecarvedilolcanpreventanthracyclinerelatedleftventricularremodelinginchildhoodcancersurvivorsathighriskfordevelopingheartfailure AT douglaspamelas rationaleanddesignofthechildrensoncologygroupcogstudyalte1621arandomizedplacebocontrolledtrialtodetermineiflowdosecarvedilolcanpreventanthracyclinerelatedleftventricularremodelinginchildhoodcancersurvivorsathighriskfordevelopingheartfailure AT bhatiasmita rationaleanddesignofthechildrensoncologygroupcogstudyalte1621arandomizedplacebocontrolledtrialtodetermineiflowdosecarvedilolcanpreventanthracyclinerelatedleftventricularremodelinginchildhoodcancersurvivorsathighriskfordevelopingheartfailure |